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Abstract 
 Recent evidence suggests that a certain type of hepatocellular carcinoma 
(HCC) is hierarchically organized by a subset of cells with stem cell features (cancer 
stem cells: CSCs). Although normal stem cells and CSCs are considered to share similar 
self-renewal programs, it remains unclear whether differentiation programs are also 
maintained in CSCs and effectively utilized for the tumor eradication. In this study, we 
investigated the effect of oncostatin M (OSM), an interleukin 6-related cytokine known 
to induce the differentiation of hepatoblasts into hepatocytes, on liver CSCs. OSM 
receptor (OSMR) expression was detected in the majority of epithelial cell adhesion 
molecule-positive (EpCAM+) HCC with stem/progenitor cell features. OSM treatment 
resulted in the induction of hepatocytic differentiation of EpCAM+ HCC cells by 
inducing signal transducer and activator of transcription 3 activation, as determined by a 
decrease in stemness-related gene expression, a decrease in EpCAM, α-fetoprotein, and 
cytokeratin 19 protein expressions, and an increase in albumin protein expression. 
OSM-treated EpCAM+ HCC cells showed enhanced cell proliferation with expansion of 
the EpCAM-negative non-CSC population. Noticeably, combination of OSM treatment 
with the chemotherapeutic agent 5-fluorouracil, which eradicates EpCAM-negative 
non-CSCs, dramatically increased the number of apoptotic cells in vitro and suppressed 
tumor growth in vivo compared with either saline control, OSM, or 5-fluorouracil 
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treatment alone. Taken together, our data suggest that OSM can be effectively utilized 
for the differentiation and active cell division of dormant EpCAM+ liver CSCs, and the 
combination of OSM and conventional chemotherapy with 5-fluorouracil efficiently 
eliminates HCC by targeting both CSCs and non-CSCs.  




It is widely accepted that cancer is a disease that develops from a normal cell 
with accumulated genetic/epigenetic changes. Although considered monoclonal in 
origin, cancer is composed of heterogeneous cellular populations. These heterogeneities 
are traditionally explained by the clonal evolution of cancer cells through a series of 
stochastic genetic events (clonal evolution model) (1). In contrast, cancer cells are 
known to have the capabilities characteristic of stem cells with respect to self-renewal, 
limitless division, and generation of heterogeneous cell populations. Recent evidence 
suggests that tumor cells possess stem cell features (cancer stem cells: CSCs) to 
self-renew and give rise to relatively differentiated cells through asymmetric division, 
and thereby form heterogeneous populations (CSC model) (2, 3). Accumulating 
evidence supports the notion that CSCs can generate tumors more efficiently in 
immunodeficient mice than non-CSCs in the case of leukemia and various solid tumors 
(4-9), although the origin of CSCs is still a controversial issue.  
Worldwide, hepatocellular carcinoma (HCC) is one of the most common 
malignancies with poor outcome (10). Recent evidence suggests that at least some 
HCCs are organized by liver CSCs in a hierarchical manner (11). Several markers have 
been identified as useful for the enrichment of liver CSCs, including side population 
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fraction (12), CD133 (13), CD90 (14), and OV6 (15). We have recently utilized 
epithelial cell adhesion molecule (EpCAM) and α-fetoprotein (AFP) to identify novel 
prognostic HCC subtypes related to certain developmental stages of human liver 
lineages (16). Among these, EpCAM-positive (+) AFP+ HCC (hepatic stem cell-like 
HCC; HpSC-HCC) is characterized by young onset of disease, activation of 
Wnt/β-catenin signaling, and poor prognosis. EPCAM is a target gene of Wnt/β-catenin 
signaling (17), and we previously identified that EpCAM+ HCC cells from primary 
HCC samples and cell lines have the features of CSCs, at least in the HpSC-HCC 
subtype (18). Thus, EpCAM appears to be a potentially useful marker for the isolation 
of liver CSCs in HpSC-HCC. 
CSCs are considered to be resistant to chemotherapy and radiotherapy (19-21), 
which may be associated with the recurrence of the tumor after treatment. These 
findings have led to the proposal of ‘destemming’ CSCs, to induce the differentiation of 
CSCs into non-CSCs or to eradicate CSCs by inhibiting the signaling pathway 
responsible for self-renewal (22). Recent studies support this proposal and suggest the 
utility of bone morphogenic proteins (BMPs), activated during embryogenesis and 
required for differentiation of neuronal stem cells, to induce differentiation of brain 
CSCs and facilitate brain tumor eradication (23, 24). However, it is still debatable 
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whether simple differentiation of CSCs effectively eradicates tumors (25). 
Oncostatin M (OSM), an interleukin (IL) 6-related cytokine produced by 
CD45+ hematopoietic cells, is known to enhance hepatocytic differentiation of 
hepatoblasts by inducing the activation of the signal transducer and activator of 
transcription 3 (STAT3) pathway (26). Although OSM, IL6 and leukemia inhibitory 
factor (LIF) share STAT3 signaling cascades, OSM is known to exploit the distinct 
hepatocytic differentiation signaling in an OSM receptor (OSMR)-specific manner (27). 
In this study, we hypothesized that OSM induces hepatocytic differentiation of liver 
CSCs through the OSMR signaling pathway. We examined OSMR expression and the 
effect of OSM in EpCAM+ HCC in terms of hepatocytic differentiation and anti-tumor 
activities.  
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Materials and Methods 
Clinical HCC specimens 
A total of 107 HCC tissues and adjacent non-cancerous liver tissues were obtained from 
patients who underwent hepatectomy for HCC treatment from 1999 to 2007 in 
Kanazawa University Hospital. These samples were formalin-fixed and 
paraffin-embedded, and used for immunohistochemistry (IHC). HCC and adjacent 
non-cancerous liver tissues were histologically diagnosed by two pathologists. An 
additional fresh EpCAM+ AFP+ HCC sample was obtained from a surgically resected 
specimen and immediately used for preparation of single-cell suspension and 
xenotransplantation. All tissue acquisition procedures were approved by the Ethics 
Committee and the Institutional Review Board of Kanazawa University Hospital. All 
patients provided written informed consent. 
 
Cell culture and reagents 
HuH1 and HuH7 cells were cultured as previously described (18). A primary HCC 
tissue was dissected and digested in 1 μg/ml type 4 collagenase (Sigma-Aldrich Japan 
K.K., Tokyo, Japan) solution at 37 °C for 15–30 min. Contaminated red blood cells 
were lysed with ammonium chloride solution (STEMCELL Technologies, Vancouver, 
BC, Canada) on ice for 5 min. CD45+ leukocytes and annexin V+ apoptotic cells were 
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removed by autoMACS-pro cell separator and magnet beads (Miltenyi Biotec K.K., 
Tokyo, Japan). EpCAM-positive and –negative cells were enriched by autoMACS-pro 
cell separator and CD326 (EpCAM) MicroBeads (Miltenyi Biotec K.K.). Recombinant 
OSM was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). 5-Fluorouracil 
(5-FU) was obtained from Kyowa Kirin (Tokyo, Japan). 
 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis  
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions. The expression of selected genes was determined in 
triplicate using the 7900 Sequence Detection System (Applied Biosystems, Foster City, 
CA, USA). Each sample was normalized relative to β-actin expression. Probes used 
were: TACSTD1, Hs00158980_m1; AFP, Hs00173490_m1; KRT19, Hs00761767_s1; 
hTERT, Hs00162669_m1; Bmi1, Hs00180411_m1; POU5F1, Hs00999632_g1; 




Whole cell lysates were prepared using RIPA lysis buffer as described previously (28). 
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Rabbit polyclonal antibodies to STAT3 (Cell Signaling Technology Inc., Danvers, MA, 
USA), rabbit polyclonal anti-OSMR antibodies H-200 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), mouse monoclonal anti-phospho-STAT3 (tyr705) antibody 
(3E2) (Cell Signaling Technology Inc.), and mouse monoclonal anti-β-actin antibody 
(Sigma-Aldrich) were used. Immune complexes were visualized by enhanced 
chemiluminescence (Amersham Biosciences Corp., Piscataway, NJ, USA) as described 
by the manufacturer. 
 
IHC and immunofluorescence (IF) analyses  
IHC was performed using Envision+ kits (DAKO, Carpinteria, CA, USA) according to 
the manufacturer’s instructions. Anti-EpCAM monoclonal antibody VU-1D9 
(Oncogene Research Products, San Diego, CA, USA) was used for detecting EpCAM. 
Goat anti-OSMR polyclonal antibodies (C-20) were obtained from Santa Cruz 
Biotechnology. Mouse anti-CYP3A4 polyclonal antibodies (Abnova, Taipei, Taiwan), 
mouse anti-CK19 monoclonal antibody (DAKO), and mouse anti-Ki-67 monoclonal 
antibody MIB-1 (DAKO) were used for detecting CYP3A4, CK19, and Ki-67, 
respectively. Samples with >5% positive staining in a given area for a particular 
antibody were considered to be positive. For IF analyses, anti-EpCAM antibody 
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(Oncogene Research Products), anti-gp130ST antibodies (Santa Cruz Biotechnology), 
and anti-phospho-STAT3 (tyr705) antibody (3E2) (Cell Signaling Technology Inc.) 
were used. Alexa 488 fluorescein isothiocyanate (FITC)-conjugated anti-mouse 
immunoglobulin G (IgG) or Alexa 568 Texas-Red-conjugated anti-goat/rabbit IgG 
(Molecular Probes) were used as secondary antibodies. Confocal fluorescence 
microscopic analysis was performed essentially as previously described (18). 
 
Fluorescence-activated cell sorting (FACS) analyses  
Cultured cells were trypsinized, washed, and resuspended in Hank’s balanced salt 
solution (Lonza, Basel, Switzerland) supplemented with 1% HEPES and 2% fetal 
bovine serum (FBS). Cells were then incubated with FITC-conjugated anti-EpCAM 
monoclonal antibody Clone Ber-EP4 (DAKO) on ice for 30 min, and analyzed using a 
FACSCalibur (BD Biosciences). Intracellular AFP, cytokeratin (CK) 19, and albumin 
levels were examined using a BD Cytofix/CytopermTM Fixation/Permeabilization Kit 
(BD Biosciences), anti-AFP mouse monoclonal antibody (Nichirei Biosciences Inc., 
Tokyo, Japan), anti-CK19 mouse monoclonal antibody (DAKO), and rabbit polyclonal 
anti- albumin antibodies (Cell Signaling Technology Inc.), respectively. 
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Cell proliferation and colony formation assay 
For cell proliferation assays, 2×103 cells were seeded in 96-well plates and cultured 
with 1% FBS Dulbecco’s modified Eagle’s meduim (DMEM) (control), 1% DMEM 
with OSM (100 ng/ml), 5-FU (2 μg/ml), or OSM (100 ng/ml) and 5-FU (2 μg/ml) for 3 
to 7 days without media changes. Cell viability was evaluated in quadruplicate using a 
Cell Titer 96 Aqueous kit (Promega, Madison, WI, USA). For colony formation assay, 
1×103 cells were harvested in a one-well Culture Slide (BD Biosciences) and cultured 
with 1% FBS DMEM (control) with or without OSM (100 ng/ml). Culture medium was 
replaced every 3 days and the colonies were fixed with ice-cold 100% methanol and 
used for IF 10 days after the initiation of treatment. 
 
RNA interference  
SiRNAs specific to OSMR (Silencer® Select SiRNA S17542) and a control siRNA 
(Silencer® Select Negative Control #1) were obtained from Ambion (Applied 
Biosystems). To each well of a six-well plate, 2×105 cells were seeded 12 hours before 
transfection. Transfection was performed using Lipofectamine 2000 (Invitrogen), 
according to the manufacturer’s instructions. A total of 100 pM siRNA duplex was used 
for each transfection. 




Cells were cultured in 1% FBS DMEM (control), 1% FBS DMEM with OSM (100 
ng/ml), 5-FU (2 μg/ml), or OSM (100 ng/ml) and 5-FU (2 μg/ml) for 3 days in six-well 
plates or in Culture Slides (BD Biosciences). Annexin V binding to cell membranes was 
visualized using Annexin V-FITC antibodies and a FACSCalibur flow cytometer (BD 
Biosciences). Activation of caspase 3 was visualized by IHC or IF using Anti-Active® 
Caspase-3 polyclonal antibodies (Promega), as described by the manufacturer. 
 
Animal studies  
Six-week-old NOD/SCID mice (NOD/NCrCRl-Prkdcscid) were purchased from Charles 
River Laboratories, Inc. (Wilmington, MA, USA). The protocol was approved by the 
Kanazawa University Animal Care and Use Committee. One million tumor cells were 
suspended in 200 μl of DMEM and Matrigel (1:1), and a subcutaneous injection was 
performed. The incidence and size of subcutaneous tumors were recorded. Intratumoral 
injection of 50 μl of phosphate-buffered saline (PBS; control), OSM (2 μg/tumor), 5-FU 
(250 μg/tumor), or OSM (2 μg/tumor) and 5-FU (250 μg/tumor) was initiated twice 
weekly 48 days after injection of tumor cells when the average volume of four tumors in 
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each group had reached 400 mm3. For histologic evaluation, tumors were formalin-fixed 
and paraffin-embedded. 
 
Statistical analyses  
The association of OSMR expression and clinicopathologic characteristics in HCC was 
examined using either Mann-Whitney U or χ2 tests. Student t-test was used to compare 
various test groups assayed by qRT-PCR analysis. All analyses were performed using 
GraphPad Prism software (La Jolla, CA, USA). 
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Results 
Distinct expression of OSMRs in HCC. 
Before exploring the effect of OSM on HCC, we examined the expression of its receptor, 
OSMR, in surgically resected HCC and adjacent non-cancerous liver tissues by IHC. 
Representative staining of OSMRs in tumor/non-tumor tissues is shown in Figure 1A. 
In general, cell surface and cytoplasmic immunoreactivity to OSMR was detected rarely 
in hepatocytes in chronic hepatitis liver (image a) but frequently in small 
hepatocyte-like cells in the stroma or transitional cells in the lobule of cirrhotic liver 
(image b), as indicated by the arrows. Note that immunoreactivity to OSMR was not 
detected in bile duct epithelia or ductular reactions where EpCAM+ hepatic progenitor 
cells are thought to accumulate (Supplemental Figure 1), suggesting that OSMRs might 
be expressed in hepatic progenitor cells committed to hepatocytes. Immunoreactivity to 
OSMRs was more strongly detected in HCC than in non-cancerous liver (image c), and 
the expression was heterogeneous in the tumor. Of note, OSMRs were detected in HCC 
cells at the invasive front area of the tumor (image d) where CSCs are known to invade 
frequently (arrows).  
 Immunoreactivity to OSMR antibodies and EpCAM antibodies was detected in 
66 (61.7%) and 38 (35.5%) of 107 HCC specimens, respectively. The 
clinicopathological characteristics of OSMR+ and -negative (-) HCC cases are shown in 
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Table 1. OSMR+ HCC was characterized by high serum AFP values (P = 0.009), poorly 
differentiated morphology (P < 0.0001), and a high frequency of EpCAM+ HCCs (P = 
0.024), suggesting that the OSMR is expressed in HCC with stem/progenitor cell 
features. OSMR+ HCC was also characterized by young onset of disease and male 
dominance, although these features did not reach statistical significance (P = 0.052 and 
0.058, respectively). OSMR was more frequently detected in EpCAM+ HCCs (76.3%) 
than in EpCAM- HCCs (53.7%). Expression of OSMR and EpCAM was further 
investigated by double IF analysis, and immunoreactivity to OSMR was detected in 
both EpCAM+ normal hepatic progenitors (Figure 1B) and EpCAM+ HCC cells (Figure 
1C). These data suggest that although OSMR is more widely expressed than EpCAM in 
HCC, OSMR is frequently expressed in EpCAM+ normal hepatic progenitors and liver 
CSCs. 
 
OSM induces hepatocytic differentiation of EpCAM+ HCC. 
Because OSMR was expressed in the majority of EpCAM+ HCCs, we investigated the 
effect of OSM on EpCAM+ HCC cell lines. First, we examined the expression of OSMR 
and its signal transducer glycoprotein 130 (gp130) in EpCAM+ AFP+ HCC cell lines 
HuH1 and HuH7 by IF (Figure 2A). Both gp130 and OSMR protein expressions were 
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detected in these cells, consistent with the IHC data. Because OSM is known to induce 
the hepatocytic differentiation of hepatoblasts in a STAT3-dependent manner, we 
investigated the effect of OSM on phospholyration of STAT3 in HuH1 and HuH7 cells 
by IF and Western blotting. Incubation of HCC cells for 1 hour with OSM at a 
concentration of 100 ng/ml resulted in the induction and nuclear accumulation of 
phospholyrated STAT3 (pSTAT3) compared with the control (Figure 2B and 2C). We 
examined the effect of OSM on the EpCAM+ cell population in HuH1 and HuH7 cells. 
We first labeled HuH1 and HuH7 cells with CD326 (EpCAM) MicroBeads and 
FITC-conjugated anti-EpCAM antibodies (Clone Ber-EP4) and performed 
positive/negative selection using magnetic activated cell sorting (MACS) to determine 
the appropriate gating criteria for EpCAM-high (designated as EpCAM+) and 
–low/negative (designated as EpCAM−) cell population (Figure 2D upper panels). It is 
interesting that OSM treatment (100 ng/ml for 72 hours) diminished the EpCAM+ cell 
population from 50.7% to 10.1% in HuH1 and from 55.2% to 28.8% in HuH7 cells 
when the same constant gating criteria was applied (Figure 2D lower panels). 
 We used RNA interference to investigate whether the decrease in EpCAM+ 
cells by OSM treatment depends on the expression of OSMR. Transfection of siRNAs 
specific to OSMR (Si-OSMR) resulted in the knockdown of target genes compared with 
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the control (Si-Control) in HuH1 and HuH7 cells 48 hours after transfection 
(Supplemental Figure 2A). We further confirmed the decrease of OSMR protein 
expression by IF and Western blotting 72 hours after transfection (Supplemental Figure 
2B and 2C). When we treated these HuH1 and HuH7 cells with OSM (100 ng/ml) for 1 
hour, we observed the decrease of pSTAT3 by OSMR gene silencing compared with the 
control (Supplemental Figure 2C). Furthermore, OSM-mediated decrease in the number 
of EpCAM+ cells was inhibited by OSMR gene silencing (Supplemental Figure 2D), 
suggesting that OSM exploits the diminution of EpCAM+ cells through the activation of 
the OSMR signaling pathway in EpCAM+ HCC. 
 We further examined the effect of OSM on hepatocytic differentiation by 
qRT-PCR and FACS analyses. OSM treatment in HuH1 cells reduced the expression of 
hepatic progenitor -related genes including AFP, KRT19 (encoding CK19), and TERT 
(encoding telomerase reverse transcriptase; TERT) (Figure 3A). OSM treatment further 
reduced the expression of BMI1 and POU5F1 (encoding Oct4), which is known to be 
expressed and required for self-renewal in embryonic stem cells. OSM treatment also 
increased the expression of the hepatocyte marker CYP3A4. Furthermore, OSM 
treatment reduced AFP+ and CK19+ cells and increased albumin+ cells compared with 
the untreated control, as evaluated by the geometric mean of the fluorescence intensities 
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of whole cells analyzed by intracellular FACS (Figure 3B). Similar results were 
obtained in HuH7 cells (data not shown) and, taken together, these data suggest that 
OSM induced the hepatocytic differentiation of EpCAM+ HCCs. 
 
Hepatocytic differentiation of EpCAM+ HCC by OSM augments cell proliferation.  
In general, normal stem cells are more quiescent than differentiated cells in terms of cell 
division. We therefore evaluated the effect of OSM on cell proliferation in HuH1 and 
HuH7 cells. It is interesting that OSM treatment for 10 days resulted in the larger colony 
formation following treatment with OSM (100 ng/ml) than the untreated control. Of 
note, the majority of cells comprising these larger colonies was EpCAM-, or had low 
expression levels, whereas a subset of untreated control cells maintained high EpCAM 
expression (Figure 3C). Similar results were obtained when cell proliferation was 
examined using an (3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
) tetrazolium (MTS) assay and Ki-67 labeling index (Figure 3D). OSM modestly 
enhanced cell proliferation (upper panels) and increased Ki-67-positive cells (middle 
and lower panels) compared with the untreated control in both HuH1 and HuH7 cells 
with statistical significance (Figure 3D).  
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OSM treatment increases chemosensitivity of EpCAM+ HCC.  
The above-mentioned data imply that although OSM may induce the hepatocytic 
differentiation of dormant EpCAM+ liver CSCs, OSM treatment alone may instead 
enhance cell proliferation through expansion of amplifying differentiated cancer cells in 
vitro, raising the question of efficacy of differentiation therapy in EpCAM+ HCC. 
Because rapidly amplifying cells are considered to be more sensitive to 
chemotherapeutic agents, we investigated the effect of combining OSM treatment with 
conventional chemotherapy to target both dormant CSCs and amplifying non-CSCs. We 
have shown that 5-FU treatment alone can diminish EpCAM- non-CSCs that result in 
the enrichment of EpCAM+ CSCs in HCC (18). We therefore explored the effect of 
5-FU in combination with OSM on EpCAM+ HCC cell proliferation and apoptosis in 
vitro.  
 When HuH1 and HuH7 cells were treated with OSM alone and cultured for 7 
days, cell proliferation was modestly increased compared with the untreated control 
(Figure 4A). In contrast, 5-FU treatment clearly inhibited cell proliferation. Noticeably, 
combination of OSM and 5-FU effectively suppressed cell proliferation in HuH1 and 
HuH7 cells (Figure 4A). We further investigated the effects of OSM and 5-FU on 
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apoptosis, evaluated by annexin V binding to cell membranes and the activation of 
caspase 3 (Figure 4B and C). Although OSM treatment alone had a small effect on 
induction of apoptosis, 5-FU treatment induced annexin-V+ and activated caspase 3+ 
cells more than in the control. Combination of OSM and 5-FU most strongly induced 
apoptosis in both HuH1 and HuH7 cells with statistical significance. 
 Finally, we investigated the effect of OSM on EpCAM+ HCC in vivo using a 
primary HCC specimen and cell lines. Single-cell suspensions from primary EpCAM+ 
HCC cells (1×106 cells) were injected into 6-week-old male NOD/SCID mice, and these 
cells formed subcutaneous tumors 48 days after transplantation. Subsequently, 50 μl of 
PBS, OSM (2 μg/tumor), 5-FU (250 μg/tumor), or OSM (2 μg/tumor) and 5-FU (250 
μg/tumor) solution were injected directly in each tumor twice a week. Although OSM 
treatment alone showed weak tumor suppressive effects, the changes in tumor size 
demonstrated no significant difference compared with the control (Figure 5A). Similarly, 
5-FU treatment alone showed limited tumor suppressive effects. However, combination 
of OSM with 5-FU showed marked inhibition of tumor growth compared with PBS 
control or 5-FU alone (P = 0.02 and 0.05, respectively). IHC analysis of xenografted 
tumors showed that OSM treatment decreased the number of EpCAM+ or CK19+ cells 
and increased CYP3A4+ cells in vivo (Supplemental Figure 3A and 3B). FACS analysis 
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of xenografted tumors further confirmed the decrease of EpCAM+ cell population by 
OSM treatment in vivo (Supplemental Figure 3C). IHC analysis revealed that 
combination of OSM with 5-FU strongly induced the activation of caspase 3 compared 
with PBS control, OSM, or 5-FU (Figure 5B). Taken together, these data suggest that 
hepatocytic differentiation of EpCAM+ HCC cells induced by OSM was the most 
effective for inhibition of tumor growth in vivo when the conventional 
chemotherapeutic agent 5-FU was co-administered. 
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Discussion 
A growing body of evidence suggests that there are similarities between normal stem 
cells and CSCs in terms of self-renewal programs (29). We have recently reported that 
Wnt/β-catenin signaling augments the self-renewal and inhibits the differentiation of 
EpCAM+ liver CSCs (18). In the present study, we have shown that the OSM–OSMR 
signaling pathway is maintained in HCCs with stem/progenitor cell features. OSM 
induces the hepatocytic differentiation and activates cell division in dormant EpCAM+ 
liver CSCs (Figure 5C). Furthermore, we have demonstrated that combination of OSM 
and 5-FU effectively inhibits tumor cell growth, revealing the importance of targeting 
both CSCs and non-CSCs for eradication of the tumor. 
OSM is a pleiotropic cytokine that belongs to the IL-6 family that includes IL6, 
IL11, and LIF. These cytokines share the gp130 receptor subunit as a common signal 
transducer, and activate Janus tyrosine kinases and the STAT3 pathway. However, 
gp130 forms a heterodimer with a unique partner such as the IL6 receptor, LIF receptor, 
or OSMR, thus transducing a certain signaling uniquely induced by each cytokine (30). 
Of note, OSM is known to activate hepatocytic differentiation programs in hepatoblasts 
in an OSMR-specific manner (27), and our data demonstrated that OSM can induce 
hepatocytic differentiation and active cell proliferation in EpCAM+ HCC through 
OSMR signaling.  
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OSMR is expressed in hepatoblasts in the fetal liver (26). We have found that 
OSMR is frequently expressed in normal hepatic progenitors but is rarely detected in 
hepatocytes in adult livers. Interestingly, OSMR+ HCC was characterized by high serum 
AFP, frequent EpCAM positivity, and poorly differentiated morphology, suggesting that 
OSMR is more likely expressed in HCC with stem/progenitor cell features (16). 
Although the regulatory mechanisms of OSMR are still unclear, it is plausible that 
OSMR expression is regulated by a signaling pathway activated during the process of 
hepatogenesis. Because gp130 is known to be ubiquitously expressed, regulation of 
OSM signaling may be largely dependent on the expression status of OSMR in normal 
and tumor tissues. Recent studies have demonstrated the potential role of methylation of 
CpG islands located in OSMR promoter in colorectal cancer (31, 32). Clarification of 
OSMR promoter activity regulation including CpG methylation may provide clues for 
better understanding of hepatocytic differentiation signaling in both normal hepatic stem 
cells and CSCs. 
It has been postulated that both normal stem cells and CSCs are dormant and 
show slow cell cycles. Consistent with this, CSCs are considered to be more resistant to 
chemotherapeutic agents than non-CSCs possibly due to slow cell cycles as well as an 
increased expression of ATP-binding cassette transporters, robust DNA damage 
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responses, and activated anti-apoptotic signaling (20, 33, 34). Therefore, development 
of an effective strategy by targeting CSC pools together with conventional 
chemotherapies is essential to eradicate a tumor mass. Two strategies have been 
investigated to reduce the CSCs population in the tumor; that is, inhibition of 
self-renewal programs and activation of differentiation programs. We have 
demonstrated that hepatocytic differentiation of liver CSCs by OSM results in enhanced 
cell proliferation in vitro. We have further shown here that OSM-mediated hepatocytic 
differentiation of liver CSCs in combination with conventional chemotherapy 
effectively suppresses HCC growth. It is possible that OSM may boost anti-tumor 
activity of 5-FU by “exhausting dormant CSCs” through hepatocytic differentiation and 
active cell division. It is encouraging that similar success with differentiation therapy 
has recently been reported in several cancers (24, 35, 36). In addition, 
HNF4-α-mediated differentiation of HCC cells has recently been reported to be 
effective for eradication of HCC (37). However, although combination of OSM and 
5-FU effectively inhibited the tumor growth in our model, we could not observe the 
shrinkage of the tumor. Thus, induction of CSC’s differentiation with eradication of 
non-CSCs might not be enough for eradication of the tumor, which may suggest the 
importance of inhibiting self-renewal as well as stimulating differentiation of CSCs. 
Differentiation of EpCAM+ Liver CSCs by OSM           Yamashita T. et al. 26 
 
Because we induced the hepatocytic differentiation of the subcutaneous tumor by local 
injection of OSM, further rigorous studies are clearly required to assess the effect of 
OSM on liver CSCs and its utility for differentiation therapy in HCC.  
CSCs may acquire resistance against differentiation therapy by additional 
genetic/epigenetic changes during treatment by clonal evolution, as observed in 
conventional chemotherapy. Indeed, it has recently been suggested that BMP-mediated 
brain CSC differentiation failed in a subset of brain tumors in which BMP receptor 
promoters were methylated and silenced (23). Similarly, OSMR silencing by promoter 
methylation may result in the development of OSM-resistant clones in HCC. 
In conclusion, OSMR is expressed in certain types of HCC with stem/progenitor 
cell features, and OSM induces hepatocytic differentiation and active cell division of 
OSMR+ liver CSCs to enhance chemosensitivity to 5-FU. The clinical safety and utility 
of OSM should be evaluated in the near future. 
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Figure 1. (A) Representative images of OSMR staining in non-cancerous liver tissues 
and HCC tissues. Immunoreactivity to OSMR was not detected in hepatocytes in 
chronic hepatitis liver tissue (image a) but was detected in a subset of small 
hepatocyte-like cells in the stroma or transitional cells in the lobule (image b, arrows) of 
cirrhotic liver tissue. OSMR was more abundantly expressed in HCC than in 
non-cancerous liver (image c). OSMR+ cancer cells were disseminated in the invasive 
front area of the tumor (image d, arrows). PT: portal tract, BD: bile duct. (B and C) 
Double IF analysis of EpCAM (green) and OSMR (red) expression in non-cancerous 
(B) and HCC (C) tissues.  
 
Figure 2. (A) IF analysis of gp130 and OSMR expression in HuH1 and HuH7 cell lines. 
(B) IF analysis of phospholyrated STAT3 expression in HuH1 and HuH7 cell lines 
stimulated by OSM (100 ng/ml for 1 hour) and controls. (C) Western blotting analysis 
of whole or phospholyrated STAT3 protein expression in HuH1 and HuH7 cells 
stimulated by OSM (100 ng/ml for 1 hour), and controls. (D) FACS analysis of HuH1 
and HuH7 cells stained with FITC-conjugated anti-EpCAM antibodies. Upper panels: 
EpCAM-high (designated as EpCAM+) (yellow) and -low/negative cells (designated as 
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EpCAM−) (blue) were enriched by MACS and labeled with FITC-conjugated 
anti-EpCAM antibodies or isotype control antibodies. Lower panels: Cells were 
cultured in 1% FBS DMEM with (green) or without OSM (100 ng/ml) (orange) for 3 
days and stained with FITC-conjugated anti-EpCAM antibodies. 
 
Figure 3. (A) qRT-PCR analysis of HuH1 cells cultured in 1% FBS DMEM with (black 
bar) or without (white bar) OSM (100 ng/ml) for 3 days. (B) Intracellular FACS 
analysis of HuH1 cells cultured in 1% FBS DMEM with (green line) or without (red 
line) OSM (100 ng/ml) for 3 days. The number in the figure indicates the geometric 
mean of the fluorescence intensity on a logarithmic scale. (C) IF analysis of HuH1 and 
HuH7 cell colonies cultured in 1% FBS DMEM with or without OSM (100 ng/ml) for 
10 days. Colonies were fixed with 100% ice-cold methanol and stained with 
FITC-conjugated anti-EpCAM antibodies. (D) Upper panels: Cell proliferation assay of 
HuH1 and HuH7 cells cultured in 1% FBS DMEM with (black bar) or without (white 
bar) OSM (100 ng/ml) for 3 days. Middle and lower panels: IF analysis of HuH1 and 
HuH7 cells cultured in 1% FBS DMEM with or without OSM (100 ng/ml) for 3 days. 
Cells were fixed with 100% ice-cold methanol and stained with anti-Ki-67 antibodies. 
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Figure 4. (A) Cell proliferation assay of HuH1 and HuH7 cells cultured in 1% FBS 
DMEM with OSM (100 ng/ml) (light gray bar), 5-FU (2 μg/ml) (gray bar), OSM (100 
ng/ml) and 5-FU (2 μg/ml) (black bar), or PBS as control (white bar) for 7 days. (B) 
FACS analysis of HuH1 and HuH7 cells stained with FITC-conjugated anti-Annexin V 
antibodies. Cells were cultured in 1% FBS DMEM with OSM (100 ng/ml) (green line), 
5-FU (2 μg/ml) (blue line), OSM (100 ng/ml) and 5-FU (2 μg/ml) (red line), or PBS as 
control (gray line) for 3 days. (C) Left panels: IF analysis of HuH1 and HuH7 cells 
stained with anti-active-caspase 3 antibodies. Cells were cultured in 1% FBS DMEM 
with OSM (100 ng/ml), 5-FU (2 μg/ml), OSM (100 ng/ml) and 5-FU (2 μg/ml), or PBS 
control for 3 days. Right panels: Bar graphs indicating the percentages of active-caspase 
3 positive cells. 
 
Figure 5. (A) Effect of PBS, OSM, 5-FU, and OSM plus 5-FU injections on the growth 
of primary EpCAM+ AFP+ HCC xenograft tumors in NOD/SCID mice (n = 4 in each 
group). Intratumoral injection of 50 μl PBS, OSM (2 μg/tumor), 5-FU (250 μg/tumor), 
or OSM (2 μg/tumor) and 5-FU (250 μg/tumor) was initiated 48 days after 
transplantation twice per week. (B) Representative images of activated caspase 3 
staining of xenograft tumors in each treatment group (PBS: image a, OSM: image b, 
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5-FU: image c, OSM and 5-FU, image d). (C) A schematic diagram of the effect of 
OSM on EpCAM+ liver CSCs. Dormant EpCAM+ liver CSCs with OSMR expression 
respond to OSM and differentiate into rapidly dividing EpCAM- non-CSCs that are 
highly sensitive to 5-FU. 
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(n = 66) 
OSMR-
(n = 41) P-value*
Age (years, mean ± SE) 62.7 ± 1.3 66.4 ± 1.3 0.052 
Sex (male/female) 55/11 27/14 0.058 
Etiology (HBV/HCV/other) 25/35/6 8/30/3 0.10 
Liver cirrhosis (yes/no) 43/23 26/15 1.0 
AFP (ng/ml, mean ± SE) 6453 ± 5901 1039 ± 935 0.009 
Histological grade**    
  I-II 3 16  
  II-III 54 20  
  III-IV 9 5 <0.0001 
Tumor size (<3cm/>3cm) 30/36 15/26 0.42 
TNM classification    
  I/II 48 31  
  III/IV 18 10 0.82 
EpCAM (positive/negative) 29/37 9/32 0.024 
*Mann-Whitney U test or χ2 test 
**Edmondson-Steiner 
 
Supplemental Figure Legends 
 
Supplemental Figure 1. Double IF analysis of EpCAM (green) and OSMR (red) 
expression in non-cancerous liver. Small hepatocyte-like cells in the lobule expressed 
both EpCAM and OSMR (yellow arrows), whereas epithelial cells in ductular reaction 
expressed EpCAM (green arrows) but not OSMR.    
 
Supplemental Figure 2. (A) qRT-PCR analysis of OSMR gene expression in HuH1 and 
HuH7 cells 48 hours after transfection with Si-Control (white bar) or Si-OSMR (gray 
bar). (B) IF analysis of OSMR expression in HuH1 cells 72 hours after transfection with 
Si-Control or Si-OSMR. (C) Western blotting analysis of OSMR, phospho-STAT3 and 
beta actin expression in HuH1 and HuH7 cells 72 hours after transfection with 
Si-Control or Si-OSMR. Cells were treated with OSM (100 ng/ml) for 1 hour before 
cell lysis. (D) FACS analysis of HuH1 cells stained with FITC-conjugated anti-EpCAM 
antibodies. Twenty-four hours after transfection with each siRNA, cells were cultured in 
1% FBS DMEM with or without OSM (100 ng/ml) for 72 hours. 
 
Supplemental Figure 3. (A) Representative images of EpCAM, CYP3A4, and CK19 
staining of xenograft tumors treated with OSM (2 μg/tumor) or PBS as control. (B) A 
bar graph indicating the percentages of CK19-positive cells in xenograft tumors treated 
with OSM (2 μg/tumor) (black) or PBS (white) as control. (C) FACS analysis of 
xenograft tumor cells treated with OSM (2 μg/tumor) or PBS and stained with 
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